Member Info for Porky9

Thanks Gizzmo,

Guess this is where you are going...
We know that Novacyt will shortly release a next generation ANTIBODY test. If we look at the first gen tests on the market the majority normally involve a finger prick blood test or similar.

Will Serolgical testing then start to take place so we can establish who has had the virus already and has natural antibody protection. Will it be used for blood donors?

https://www.technologyreview.com/2020/04/15/999600/what-is-serological-testing/

Hmmmm Smell some game play here but will reply in good faith.

We know for a fact that Novacyt supply 150 countries (RNS) so even if WW was £ 82m in the H2 the fact is we have launched PROmate and SNPsig since not to mention boots on the ground stateside and a heavyweight to promote stateside sales.

I very much suspect WW sales are currently significantly higher and the landscape now VERI different

GLA

@B2HS2L

Have no concerns regarding Perkin Elmer, they are about to lose a major labs contact in California due to incompetence at every level from what i have read.

It's logical that the bigger players will try and and replicate Novacyt's products but we remain one step ahead whilst they play catch up. We can move significantly quicker and be very pro-active to the situation before they even wake up.
We are a speed boat around their oil tanker!!

@TrueBlue
That is the million dollar question. ...

If it's us the SP absolutely rockets, if its not we drift until the P2 or other material News drops

I took the gamble this afternoon that it's us and added yet again...

On the logic that downside risk to the SP is so minimal now its kind of a no brainer to buy at this level, faith in conviction and all that. See how events unfold.

GLA

Another £15k at 720
Confidence in conviction
GLA

@Naewise
Discussed on a continual basis here;

Despite the business working hard to be "An international Diagnostics group" The businesses is still lumped into the " Short Term Covid Bucket" the question that non researched investors raise often is " what else do Novacyt do?"

The perception from both investors and the market is "Will revenues dry up shortly" hence the SP is manipulated and played with by shorter's and quick time traders.

IF Novacyt can install tech into the NHS, win contracts over a longer term period, include deals in non covid areas then the sky is the limit. The possible deal talked about here today, IF it is us could be the catalyst to start that perception view change.

I get shot down for my £ 54 price target BUT if they were to land a significant contract with longevity frankly, the SP would rally and it would get properly re-rated. My price target at that point wont looks so stupid. Time will tell.

Good Luck

A Quick Precis of the government statement:-
https://www.gov.uk/government/news/groundbreaking-new-technology-to-detect-known-variants-of-concern

“identify if a positive COVID-19 sample contains a variant”
“used in addition to standard testing”
“controlling of variants of concerns is an essential part of cautiously easing lockdown”
“cases of variants of concern are detected faster”
“halving the time it takes to detect a case which is currently around 4 to 5 days for genomic sequencing”
“allow contacts of positive cases to be traced sooner”
“our goal is to eventually test every COVID positive sample for mutations, that indicate known variants”
“developing these new genotype assays mitigate the risk posed by imported variants”
“Genotype assays would complement existing surveillance work”

So clearly its screening all positive tests in ADDITION to pick up variants.
https://twitter.com/NovacytGroup/status/1373276409523757056

And the killer Message:-
https://twitter.com/NovacytGroup/status/1372579841338441730
“Our portfolio of SNPsig® assays will allow on-site detection of all variants of concern (UK, South Africa, Brazil), within 2 hours”

https://www.primerdesign.co.uk/products-hub/snpsig-sars-cov-2-voc-identification-kits

QUESTION: What might this be worth ?

Little tree shake today, need to be greedy here, i would be amazed if this is not us. Everything fits...

Well unless i'm missing something here:-

Extract:-
"This new technology will mean that cases of variants of concern are detected faster than before – potentially halving the time it takes to detect a case, which is currently around 4 to 5 days for genomic sequencing. By notifying those affected more quickly, this could allow contacts of positive cases to be traced sooner, breaking the chains of transmission, stop the spread of variants and saving lives"

If you run Novacyt's SNP assay on a Q machine you get a result within an hour and that result clearly identifies the Variant of concern - so we have this already?

So either the government have just woken up to what Novacyt are doing and creating attention like some over excited schoolboy OR some other company is in their doing something similar to what we offer?

If it were a Novacyt test i would expect a run on the SP this afternoon as those "in the know" start buying shares. As Our SP is doing nothing it could be some other form of variant extraction? We should find out soon enough

Meanwhile recruitment continues in high volume so something still cooking on gas at Novacyt for sure

Interesting

Media in Overdrive
https://www.gov.uk/government/news/groundbreaking-new-technology-to-detect-known-variants-of-concern

Is Poidster around?

With me being the eternal optimist it does sound like something we may be involved with but there are other methods I have read about. Really need a scientific reply here

From what I have read It looks like it all starts from a PCR test process? Can’t be sure but this wiki article kind of alludes to that. In which case it could well be something - maybe another reason for recruiting so many Staff in NHS territories.
https://en.m.wikipedia.org/wiki/SNP_genotyping

I do hope so, please let it be use, wouldn’t that be left of field...

BBC News Article details how Control can be taken.
https://www.bbc.co.uk/news/uk-56455030
The death toll in South Korea, a country of 52 million people, stands at 1,693
The death toll in the UK, a country of 68 million people, stands at 126,155

PCR Test with result in under 4 hrs Mandatory (UK - LFTs with false results)
Trace details so they know EXACTY who you are and where you live (UK - Trace service next to hopeless)
Strict Quarantine - You cannot leave your home at all during that period (UK - Less than 20% asked to self-isolate will fully quarantine)
Care Homes Protected - Strict testing at day one (UK- we even discharged people from hospitals into care homes without tests)

The ONLY thing we got right in the UK is the Vaccination Program BUT we can get back on track if we sort Track and Trace and couple it with Gold standard testing. We have the resource to do it.

@Wilson63
Indeed. Good Luck to you. Arn't we supposed to say Break a leg or something? probably not a good idea, lol
You will be back in no time, hopefully to a good lift in the SP to put an extra smile on your face!! Take Care

@B2HS3L
I always knew you were an artist :)
Bloody Impressive

That is a most serious set back in Brazil.
To put this into perspective, We are talking a population of 212m in Brazil, we are 68m hence three times our size.
The other factor is low Vaccination take up in Brazil, just 6m. But that's not just born out of vaccination supply issues, it's due to miss information on SM and a reluctance to be vaccinated.
I just can't get my head around it myself, the hospitals are over flowing and some are declining being vaccinated.

Discussed last week
Genmark was delivering $188m Revenue at 40% margin
https://www.globenewswire.com/news-release/2021/02/25/2182948/0/en/GenMark-Diagnostics-Reports-Fourth-Quarter-and-Full-Year-2020-Results.html
And is acquired by Roche for $1.8m
https://www.fiercebiotech.com/medtech/roche-to-pick-up-genmark-diagnostics-1-8b-infectious-disease-testing-deal

Just illustrates how ridiculously low our Share Price is in relation to true value.
If you applied the same valuation metric to Novacyt we would have a mcap in the region £4bn not £ 500m
Time for our Share Price to re-rate.

See what next week brings. GLA

@crl123
The answer just specifically for Schools is PCR Saliva testing imo. You only need to look at the AstraZeneca data with Novacyt, other similar reports confirm same:-
Total accuracy
Massive take up rate, spit and go, simple to operate
Results to mobile/email next day before school starts.

The high volume moonshot labs can turn the results around quickly. All teachers need to do is send the kids home with the packs and instruct them to do it twice a week and send back to the lab with each students result emailed to both the parent and the school.

The current policy is a total car crash but rather than fix it, i think they will just use up some Innova LFT stock and then close down school testing. The continued spread of the virus in schools and interruption will just be seen as collateral damage. its ONLY if the virus spread gets to a level that creates high levels of complaints that they may address it. I actually don't think they care less frankly.

@Bluelight
With you all the way, I'm still standing by my £ 54 target.....
This is just the start of the next step up

@crl123
LMOL Show off
I had a CB radio, my handle was Moonshine “One Four, One Four for a Copy” no idea what happened to, probably show up on antiques roadshow.

Looking like further expansion and so the Recruitment drive continues
https://twitter.com/TotemAnalyse/status/1372960214320869380
59 Open Vacancies on Linked-in
Speaks volumes,
It's going to get interesting very soon,
GLA

Biograd Laboratories - https://www.biograd.co.uk/

I have seen the laboratories first-hand at the site in Liverpool and met Natalie Kenny who I can tell you is one smart cookie in my opinion. An incredible scientist.

She has outstanding and significant experience in toxicology. For those not scientifically minded this relates to how chemical substances affect living organisms and the practice of diagnosing and treating exposures to toxins. So essential knowledge supporting R&D and diagnostics services.

If Novacyt were able to do a deal here it would be a good strategic move imo and add some fantastic talent to the Novacyt business.

The lab in Liverpool historically was supporting Liverpool University, it was training next generation scientists, students and staff from all kinds of employers that required specific advanced lab training hence would also be useful to Novacyt should they need to supply staff say to mobile labs as part of a service deal in the future.

Since the Covid pandemic Biograd have obviously moved further into testing services but ultimately the labs could support numerous other screening services, and this is where Novacyt come in. With the further expansion into the NHS and other fields, the network of labs would support Novacyt’s own R&D, significantly expand their services and deliver a complete 360 solution.

A deal here would add significant value to both parties.

Pork’s

At the start of every Regulatory News Service release the company describes itself as

“An international specialist in clinical diagnostics”

BUT the market does not read this it simply assumes its just another “Covid Play” and possibly a short term one at that. Hence quick smash and grab raids on the stock rather than attracting more longer-term support.

We know from numerous exchanges that the company has a clear objective to become a major mid market entity in the diagnostics space. I am confident they will do that if they are not swallowed up whole by a whale before they get there.

Now due to the Covid pandemic, demand for Covid tests worldwide has obviously gone into the stratosphere and likely to remain that way for some time but as a direct consequence of this, the bulk of Novacyts revenues still come from this sector which again endorses the “Covid Play” perception.

The work in sequencing and the world class diagnostics solutions delivered are helping them set the business apart from covid plays but they now need to make acquisitions to be seen more as a more general established Diagnostics group, than being perceived as a one trick pony, especially if they are to reap the rewards and be valued as such.

The business is already being compared to mega players like Perkin Elmer, Roche, Qiagen etc and it can and will eat at this top table, but it needs to expand the verticals within its Diagnostics fields.

The DHSC contract will deliver endorsement of its significance in testing for the longer term, which I expect will land shortly and materially bolster the share price but the strategic moves the business makes in addition could significantly add to this, change the perception of the business, and really move them up another gear to be truly perceived as they deserve to be, as a market leading diagnostics group.

Exciting times ahead.

Pork's